Last reviewed · How we verify
Fimasartan and Rosuvastatin
Fimasartan blocks angiotensin II receptors to lower blood pressure, while rosuvastatin inhibits HMG-CoA reductase to reduce cholesterol synthesis.
Fimasartan blocks angiotensin II receptors to lower blood pressure, while rosuvastatin inhibits HMG-CoA reductase to reduce cholesterol synthesis. Used for Hypertension with dyslipidemia, Cardiovascular risk reduction in patients requiring both antihypertensive and lipid-lowering therapy.
At a glance
| Generic name | Fimasartan and Rosuvastatin |
|---|---|
| Sponsor | Boryung Pharmaceutical Co., Ltd |
| Drug class | Angiotensin II receptor blocker + HMG-CoA reductase inhibitor |
| Target | Angiotensin II type 1 receptor (AT1R) and HMG-CoA reductase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
This is a fixed-dose combination where fimasartan acts as an angiotensin II receptor blocker (ARB) to reduce vasoconstriction and lower blood pressure, and rosuvastatin is a statin that inhibits the rate-limiting enzyme in cholesterol biosynthesis to reduce LDL cholesterol levels. Together, they provide complementary cardiovascular protection by addressing both hypertension and dyslipidemia.
Approved indications
- Hypertension with dyslipidemia
- Cardiovascular risk reduction in patients requiring both antihypertensive and lipid-lowering therapy
Common side effects
- Dizziness
- Headache
- Muscle pain or myalgia
- Elevated liver enzymes
- Hyperkalemia
Key clinical trials
- Fimasartan and Rosuvastatin for Hypertension and Dyslipidemia Control
- Clinical Study to Evaluate Adherence Improvement Fixed-dose Combination of Olostar Tab. in Patients With Hypertension and Dyslipidemia (PHASE4)
- Combination of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia (PHASE3)
- A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Fimasartan and Rosuvastatin in Healthy Male Subjects (PHASE1)
- Comparison of Fimasartan Versus Amlodipine Therapy on Carotid PlaquE Inflammation (PHASE4)
- A Study to Compare the Pharmacokinetics and Safety of a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin (PHASE1)
- A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Rosuvastatin in Comparison to Each Component Administered Alone in Patients With Essential Hypertension and Dyslipidemia (PHASE3)
- A Study to Compare the Pharmacokinetics and Safety of a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |